Syntimmune

Syntimmune is advancing novel therapies based on its leading position in the biology of the neonatal Fc receptor (FcRn). FcRn is a well-validated target for IgG-mediated autoimmune diseases and represents a central common pathway capable of generating abnormal IgG responses. Syntimmune's lead candidate, SYNT001, is a biological progress in IND-initiating studies through the specific blockade of FcRn-IgG interactions, currently in development for the treatment of IgG-mediated autoimmune diseases. Syntimmune also has two additional early-stage therapeutic programs targeting other unique aspects of FcRn biology. The Syntimmune team possesses world-class expertise in the field of FcRn biology and has successfully pioneered advanced biologics targeting FcRn, including currently approved treatments on the market.